PCH
RARE icon

Polar Capital Holdings’s Ultragenyx Pharmaceutical RARE Stock Holding History

Polar Capital Holdings’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-556,628
Closed -$12.8M – 270
2025
Q4 		$12.8M Sell
556,628
-27,082
-5% -$891K 0.05% 183
2025
Q3 		$17.6M Buy
583,710
+32,327
+6% +$969K 0.08% 163
2025
Q2 		$20M Sell
551,383
-100,000
-15% -$3.61M 0.1% 145
2025
Q1 		$23.6M Buy
+651,383
New +$27.1M 0.14% 137

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Polar Capital Holdings's RARE Position: Q1 2026 in Review

Polar Capital Holdings sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 556,628 shares — an estimated $12.8M sold.

Polar Capital Holdings first reported a position in RARE in Q1 2025 and held it in 4 quarters. The position peaked at $23.6M in Q1 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Polar Capital Holdings reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • Polar Capital Holdings sold 556,628 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $12.8M.
  • Polar Capital Holdings first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and held it in 4 quarters.
  • Polar Capital Holdings's Ultragenyx Pharmaceutical position peaked at $23.6M in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Polar Capital Holdings's 13F filing for Q1 2026, filed 15 May 2026.